Orthocell Fortifies Cash Position for US Expansion With A$3.05 Million R&D Tax Refund

Leading regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) has secured an Australian Research and Development (R&D) Tax Incentive refund amounting to A$3.05 million for the fiscal year 2022-2023.

Investing.com Apr 15 09:54

Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%

Orthocell (ASX:OCC) secured a AU$3 million rebate from the Australian government's research and development tax incentive scheme, according to a Monday filing with the Australian Securities Exchange.

MT NewswiresApr 15 09:31

Orthocell Revenue Soars 19% to AU$1.61 Million in Q1

Orthocell (ASX:OCC) posted its quarterly report for the period ended March 31 showing revenue rose 19% to AU$1.61 million compared with a year earlier, according to a Tuesday Australian bourse filing.

MT NewswiresApr 9 10:27

Orthocell Ltd Reports Solid Revenue Growth

TipRanksApr 8 08:48

Orthocell Moves Closer to US Market Clearance and Sales | ASX:OCC, OTC:ORHHF

Proactive InvestorsMar 26 20:50

Orthocell Completes First Stage of Remplir US Market Authorization Study

Orthocell (ASX:OCC) has completed the first stage of its Remplir US market authorization study, allowing the regenerative medicine company to move forward with the remaining two stages, according to a

MT NewswiresMar 25 07:23